Various clinical studies have been applied to MASLD/MASH, and meta-analyses suggest that l-carnitine treatment can significantly improve serum ALT and AST levels as well as NAFLD activity scores in patients with MASH.10 The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.